Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer
- 20 March 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (9), 1038-1042
- https://doi.org/10.1200/jco.2006.07.3361
Abstract
Purpose Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known. Patients and Methods In a 12-month study, 40 men with nonmetastatic prostate cancer who were receiving a GnRH agonist and had T scores more than −2.5 were randomly assigned to zoledronic acid (4 mg intravenously on day 1 only) or placebo. BMD of the posteroanterior lumbar spine and proximal femur were measured by dual-energy x-ray absorptiometry. Results Mean (± SE) BMD of the posteroanterior lumbar spine decreased by 3.1% ± 1.0% in men assigned to placebo and increased by 4.0% ± 1.0% in men assigned to zoledronic acid (P < .001). BMD of the total hip decreased by 1.9% ± 0.7% in men assigned to placebo and increased by 0.7% ± 0.5% in men assigned to zoledronic acid (P = .004). Similar between-group differences were observed for the femoral neck and trochanter. Serum N-telopeptide, a marker of osteoclast activity, decreased significantly after zoledronic acid treatment. Conclusion In men receiving a GnRH agonist, a single treatment with zoledronic acid significantly increased BMD and durably suppressed serum N-telopeptide levels for 12 months. Annual zoledronic acid may be a convenient and effective strategy to prevent bone loss in hypogonadal men.Keywords
This publication has 21 references indexed in Scilit:
- Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapyExpert Opinion on Investigational Drugs, 2006
- Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate CancerJournal of Urology, 2006
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate CancerJournal of Clinical Oncology, 2005
- Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinomaCancer, 2005
- Renal Failure with the Use of Zoledronic AcidThe New England Journal of Medicine, 2003
- Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate CancerJournal of Urology, 2003
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityThe New England Journal of Medicine, 2002
- BONE MINERAL DENSITY IN MEN TREATED WITH SYNTHETIC GONADOTROPIN-RELEASING HORMONE AGONISTS FOR PROSTATIC CARCINOMAJournal of Urology, 1999
- The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinomaCancer, 1998